SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes.

ABSTRACT:

Introduction

Inflammation has been associated with depression and differential antidepressant (AD) treatment response. Soluble urokinase plasminogen activator receptor (suPAR) is a novel measure of chronic inflammation. We investigated whether suPAR is associated with depression severity and AD response.

Methods

We included 90 patients with major depressive disorder (MDD) who participated in a part-randomized clinical trial of 26 weeks of treatment with escitalopram or nortriptyline. suPAR levels were measured in serum samples collected at baseline and after 8, 12 and 26 weeks. Mixed effects models for the association between suPAR levels and AD response were performed. By merging with Danish nationwide registers, we included information on psychiatric hospital contacts duri

SUBMITTER: Haupt TH 

PROVIDER: S-EPMC10507069 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature